Literature DB >> 17879893

The ACTN3 gene in elite Greek track and field athletes.

I D Papadimitriou1, C Papadopoulos, A Kouvatsi, C Triantaphyllidis.   

Abstract

The study of genetic influence in the making of an Olympic champion is still in its nascence, but recent work has provided findings regarding the association of the ACTN3 gene on athletic performance. The aim of this study was to examine genetic differences among elite Greek track and field athletes by analysing a mononucleotide polymorphism in exon 15 of the ACTN3 gene. Results showed that ACTN3 genotype and allele frequencies in the top power-oriented athletes were statistically significantly different from those in a representative random sample of the Greek population: the frequency of the RR ACTN3 genotype in power-oriented athletes vs. the general population was 47.94 % vs. 25.97 %. This result was even more prominent for comparison of the subgroup of sprinters to controls. The results suggest an overall strong association between the presence of the RR genotype and elite power performance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17879893     DOI: 10.1055/s-2007-965339

Source DB:  PubMed          Journal:  Int J Sports Med        ISSN: 0172-4622            Impact factor:   3.118


  37 in total

Review 1.  Animal models of muscular dystrophy.

Authors:  Rainer Ng; Glen B Banks; John K Hall; Lindsey A Muir; Julian N Ramos; Jacqueline Wicki; Guy L Odom; Patryk Konieczny; Jane Seto; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 2.  The genetics of sports injuries and athletic performance.

Authors:  Nicola Maffulli; Katia Margiotti; Umile Giuseppe Longo; Mattia Loppini; Vito Michele Fazio; Vincenzo Denaro
Journal:  Muscles Ligaments Tendons J       Date:  2013-08-11

Review 3.  Genomics and genetics in the biology of adaptation to exercise.

Authors:  Claude Bouchard; Tuomo Rankinen; James A Timmons
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

4.  The Effect of ACTN3 Gene Doping on Skeletal Muscle Performance.

Authors:  Fleur C Garton; Peter J Houweling; Damjan Vukcevic; Lyra R Meehan; Fiona X Z Lee; Monkol Lek; Kelly N Roeszler; Marshall W Hogarth; Chrystal F Tiong; Diana Zannino; Nan Yang; Stephen Leslie; Paul Gregorevic; Stewart I Head; Jane T Seto; Kathryn N North
Journal:  Am J Hum Genet       Date:  2018-04-26       Impact factor: 11.025

Review 5.  Genes and elite athletes: a roadmap for future research.

Authors:  Nir Eynon; Jonatan R Ruiz; José Oliveira; José Alberto Duarte; Ruth Birk; Alejandro Lucia
Journal:  J Physiol       Date:  2011-05-03       Impact factor: 5.182

6.  ACE I/D, ACTN3 R577X, PPARD T294C and PPARGC1A Gly482Ser polymorphisms and physical fitness in Taiwanese late adolescent girls.

Authors:  Li-Ling Chiu; Tzu-Wen Chen; Sandy S Hsieh; Ling-Ling Hsieh
Journal:  J Physiol Sci       Date:  2012-01-14       Impact factor: 2.781

7.  Genetics and the Elite Athlete: Our Understanding in 2020.

Authors:  Rakesh John; Mandeep Singh Dhillon; Sidak Dhillon
Journal:  Indian J Orthop       Date:  2020-03-11       Impact factor: 1.251

8.  ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling.

Authors:  Jane T Seto; Kate G R Quinlan; Monkol Lek; Xi Fiona Zheng; Fleur Garton; Daniel G MacArthur; Marshall W Hogarth; Peter J Houweling; Paul Gregorevic; Nigel Turner; Gregory J Cooney; Nan Yang; Kathryn N North
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 9.  Genes for elite power and sprint performance: ACTN3 leads the way.

Authors:  Nir Eynon; Erik D Hanson; Alejandro Lucia; Peter J Houweling; Fleur Garton; Kathryn N North; David J Bishop
Journal:  Sports Med       Date:  2013-09       Impact factor: 11.136

10.  Association of the ACTN3 R577X polymorphism with power athlete status in Russians.

Authors:  Anastasiya M Druzhevskaya; Ildus I Ahmetov; Irina V Astratenkova; Viktor A Rogozkin
Journal:  Eur J Appl Physiol       Date:  2008-05-10       Impact factor: 3.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.